[go: up one dir, main page]

MX2010005385A - Medicamentos topicos para la terapia antimicotica. - Google Patents

Medicamentos topicos para la terapia antimicotica.

Info

Publication number
MX2010005385A
MX2010005385A MX2010005385A MX2010005385A MX2010005385A MX 2010005385 A MX2010005385 A MX 2010005385A MX 2010005385 A MX2010005385 A MX 2010005385A MX 2010005385 A MX2010005385 A MX 2010005385A MX 2010005385 A MX2010005385 A MX 2010005385A
Authority
MX
Mexico
Prior art keywords
topical drugs
antifungal therapy
antifungal
drugs
active substance
Prior art date
Application number
MX2010005385A
Other languages
English (en)
Inventor
Marianne Petersen-Braun
Sabine Glaser
Norbert-Heinz Becker
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of MX2010005385A publication Critical patent/MX2010005385A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a medicamentos tópicos para la terapia antimicótica que contienen al menos un principio activo antimicótico y al menos un principio activo seleccionado del grupo que comprende ácido pantoténico y derivados del ácido pantoténico en una combinación fija.
MX2010005385A 2007-11-17 2008-11-15 Medicamentos topicos para la terapia antimicotica. MX2010005385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07022353 2007-11-17
PCT/EP2008/009686 WO2009062746A2 (de) 2007-11-17 2008-11-15 Topische arzneimittel zur antimykotischen therapie

Publications (1)

Publication Number Publication Date
MX2010005385A true MX2010005385A (es) 2010-07-30

Family

ID=40214317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005385A MX2010005385A (es) 2007-11-17 2008-11-15 Medicamentos topicos para la terapia antimicotica.

Country Status (5)

Country Link
EP (1) EP2222319A2 (es)
AU (1) AU2008323165A1 (es)
CA (1) CA2705815A1 (es)
MX (1) MX2010005385A (es)
WO (1) WO2009062746A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511040B2 (en) 2007-06-20 2016-12-06 The Trustees Of Columbia University In The City Of New York Skin and surface disinfectant compositions containing botanicals
US8932624B2 (en) 2007-06-20 2015-01-13 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
US9687429B2 (en) 2007-06-20 2017-06-27 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing low concentrations of botanicals
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
WO2011002929A1 (en) * 2009-06-30 2011-01-06 The Trustees Of Columbia University In The City Of New York Antimicrobial/preservative compositions comprising botanicals
IT1400726B1 (it) * 2009-07-24 2013-07-02 Vi Rus S R L Composizione di un'emulsione ad uso topico a base di clotrimazolo, clorexidina digluconato,acido salicilico,allantoina,pantenolo,zinco,acido glicirretico,olio di mandorle dolci,olio di riso,mentile lattato indicata nel trattamento delle infezioni micotiche della cute e dei suoi annessi.
WO2011061155A1 (en) * 2009-11-17 2011-05-26 Bayer Consumer Care Ag Antifungal formulations and their use
GB201107176D0 (en) * 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
AU2012332495B2 (en) 2011-11-03 2017-06-08 The Trustees Of Columbia University In The City Of New York Composition with sustained antimicrobial activity
US9968101B2 (en) 2011-11-03 2018-05-15 The Trustees Of Columbia University In The City Of New York Botanical antimicrobial compositions
TW201330856A (zh) 2011-12-06 2013-08-01 Univ Columbia 廣效性的天然防腐組成物
JP6194003B2 (ja) 2012-10-09 2017-09-06 ザ プロクター アンド ギャンブル カンパニー 有益剤及びこれを含む組成物の特定又は評価方法
CN110151591A (zh) 2012-10-09 2019-08-23 宝洁公司 鉴定协同化妆品组合的方法
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
CN108472272A (zh) * 2015-08-17 2018-08-31 俄亥俄州国家创新基金会 用于ar-12的增强的透甲递送的方法和组合物
WO2017091167A1 (en) * 2015-11-28 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Topical pharmaceutical composition comprising fusidic acid, isoconazole, dexpanthenol and hydrocortisone
KR102217617B1 (ko) * 2020-08-14 2021-02-19 비엘엔에이치 주식회사 백선의 예방 또는 치료용 약학적 조성물
CN113440483B (zh) * 2021-06-30 2023-04-07 佛山市南海东方澳龙制药有限公司 一种犬用盐酸特比萘芬喷剂及其制备方法
WO2024137780A1 (en) * 2022-12-21 2024-06-27 Yale University Pank modulators and methods of treatment using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2338248A1 (fr) * 1976-01-14 1977-08-12 Daunit Jeannine Pantothenate de zinc et procede d'obtention
RO107824B1 (ro) * 1991-01-30 1994-01-31 Maria Gaidargiu Șampon pentru păr
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
JP5170486B2 (ja) * 1998-09-10 2013-03-27 バイオイコール ア−ゲー 局所適用性産物
AU2003216034A1 (en) * 2002-01-21 2003-07-30 Slovakofarma A.S. Dermatological topical compositions and a process for the preparation thereof
DE10361022A1 (de) * 2003-12-23 2005-07-28 Merckle Gmbh Chem.-Pharm. Fabrik Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol
EP1557375A1 (de) * 2004-01-23 2005-07-27 Neubourg Skin Care GmbH & Co. KG Nageltinktur-Sprühdose

Also Published As

Publication number Publication date
CA2705815A1 (en) 2009-05-22
WO2009062746A2 (de) 2009-05-22
WO2009062746A3 (de) 2009-08-13
AU2008323165A1 (en) 2009-05-22
EP2222319A2 (de) 2010-09-01

Similar Documents

Publication Publication Date Title
MX2010005385A (es) Medicamentos topicos para la terapia antimicotica.
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
TN2012000216A1 (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
EP2123274A4 (en) MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORAGE UNIT, AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
IL202300A0 (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
IL196394A0 (en) Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
MY203648A (en) Preparations comprising amorphous emodepside
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
ZA201000187B (en) 17b-cyano-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative
ZA200802187B (en) Drug delivery system for topical administration
ZA201005398B (en) 15,16-methylene-17-(1'-propenyl)-17,3'-oxidoestra-4-en-3-one derivative,use thereof,and medicament containing said derivative
ZA201000186B (en) 17b-cyano-19-androst-4-ene derivative,use thereof and medicaments containing said derivative
WO2009010298A3 (en) Paullone derivatives and its use
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
ZA200904563B (en) Transdermal Therapeutic system for administering water-soluble active ingredients
GB0517838D0 (en) Transdermal active principle delivery means
ZA201005397B (en) 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative,use thereof,and medicament containing said derivative

Legal Events

Date Code Title Description
FA Abandonment or withdrawal